throbber
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Patentee: Acheampong,ef al.
`
`Examiner: Marcela M Cordero Garcia
`
`PATENT
`
`Patent No.: 9,248,191
`
`Group Art Unit: 1676
`
`Issue Date: February 2, 2016
`
`Confirmation No. 9616
`
`For: METHODS OF PROVIDING
`THERAPEUTIC EFFECTS USING
`CYCLOSPORIN COMPONENTS
`
`Customer No.: 51957
`
`REQUEST FOR CERTIFICATE OF CORRECTION
`
`Attn: Certificate of Correction Branch
`Commissionerfor Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`It is requested that a Certificate of Correction be issued correcting printing errors appearing
`
`in the above-identified United States patent.
`
`Pursuant to 1.20(a), the examineris authorized to charge the Certificate of Correction fee
`
`of $100.00 or any additional fees or credit overpayment to Deposit Account No. 010885.
`
`Issuance of the Certificate of Correction would neither expand nor contract the scope of the
`
`claims as properly allowed, and re-examination is not required.
`
`Respectfully submitted,
`
`Date _February 16, 2016
`
`By: /Laura L. Wine/
`Laura L. Wine
`Reg. No.: 68681
`
`TEVA - EXHIBIT 1004 (PART 1 OF 5)
`
`0001
`
`0001
`
`TEVA - EXHIBIT 1004 (PART 1 OF 5)
`
`

`

`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Patentee: Acheampong,ef al.
`
`Examiner: Marcela M Cordero Garcia
`
`Patent No.: 9,248,191
`
`Group Art Unit: 1676
`
`Issue Date: February 2, 2016
`
`Confirmation No. 9616
`
`For: METHODS OF PROVIDING
`THERAPEUTIC EFFECTS USING
`CYCLOSPORIN COMPONENTS
`
`Customer No.: 51957
`
`Attn: Certificate of Correction Branch
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Weare transmitting herewith the attached:
`
`X Request for Certificate of Correction.
`X Certificate of Correction Form - PTO-1050
`
`Please charge any additional fees or credit overpayment to Deposit Account No. 010885.
`
`Respectfully submitted,
`
`
`
`/LauraL.Wine/
`
`Date: February 16, 2016
`
`By Laura L. Wine
`Reg. No.:68681
`
`0002
`
`0002
`
`

`

`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`Page 1 of 4
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`insert - - Re-Examination - -.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`On the first page, in field (63), in column 1,
`
`in “Related U.S. Application Data”, line 4,
`
`delete “and” and insert - - which is - -, therefor.
`
`On the Page 2, in column 2, under “Other Publications”, line 9, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 1, under “Other Publications”, line 52, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 1, under “Other Publications”, line 61, delete “Muscosal”
`
`and insert - - Mucosal - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 24, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 28, delete
`
`“Polyocyethylene” and insert - - Polyoxyethylene - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 29, delete
`
`“PhysicoChemical” and insert - - Physico-Chemical - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 39, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 13, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 35, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 48, after “U.S.”
`
`0003
`
`0003
`
`

`

`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 2 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`In column 1, line 53, delete “al.” and insert - - al, - -, therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`On the Page 4, in column 2, under “Other Publications”, line 10, delete “Allegran,”
`
`and insert - - Allergan, - -, therefor.
`
`On the Page 4, in column 2, under “Other Publications”, line 43, delete “Occular” and
`
`insert - - Ocular - -, therefor.
`
`On the Page 5, in column 1, under “Other Publications”, line 58, after “Systane”
`
`insert - - Products, Systane - -.
`
`On the Page 5, in column 1, under “Other Publications”, line 59, delete “http;//” and
`
`insert - - http:// - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 22, delete “Waston” and
`
`insert - - Watson - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 31, delete “No.” and
`
`insert - - Nos. - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 33,
`
`delete “5050)(2)(13)” and insert - - 505(j)(2)(B) - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 48,
`
`delete “5050)(2)(13)” and insert - - 505(j)(2)(B) - -, therefor.
`
`In column 1, line 8, delete “13/961.828”"and insert - - 13/961,828 - -, therefor.
`
`In column 1, line 36, delete “a” and insert - - A - -, therefor.
`
`In column 1, line 37, delete “a” and insert - - A - -, therefor.
`
`In column 1, line 39, delete “2002,” and insert - - 2002 - -, therefor.
`
`0004
`
`0004
`
`

`

`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 3 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`insert - - 2-methacryloyloxyethylsulfonic - -, therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`In column 2, line 65, delete “kerapoconjunctivitis,” and
`
`insert - - keratoconjunctivitis, - -, therefor.
`
`In column 3, line 12, delete “clyclcosporin” and insert - - cyclosporin - -, therefor.
`
`In column 3, line 52, delete “were” and insert - - are - -, therefor.
`
`In column 4, line 23, After “more” insert - - of - -.
`
`In column 5, line 9, delete “kerapoconjunctivitis,” and
`
`insert - - keratoconjunctivitis, - -, therefor.
`
`In column 5, line 66, After “with” delete “a”.
`
`In column 6, line 3, delete “acetronitrile-based” and insert - - acetonitrile-based - -,
`
`therefor.
`
`In column 9, line 20, delete “each” and insert - - such - -, therefor.
`
`In column 9, line 48, delete “extant” and insert - - extent - -, therefor.
`
`In column 9, line 60, delete “benefiting” and insert - - benefitting - -, therefor.
`
`In column 10, line 22, delete “informing” and insert - - in forming - -, therefor.
`
`In column 10, line 35, delete “amphorteric” and insert - - amphoteric - -, therefor.
`
`In column 11, line 7, delete “methylhydroxyethlystarches” and
`
`insert - - methylhydroxyethylstarches - -, therefor.
`
`In column 11, line 10, delete “glucoaminoglycans” and
`
`insert - - glycosaminoglycans - -, therefor.
`
`In column 11, line 28, delete “2-methacrylolyoxyethlysulfonic” and
`
`0005
`
`0005
`
`

`

`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 4 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`In column 11, line 29, delete “2-methacryloyloxethylsulfonates” and
`
`insert - - 2-methacryloyloxyethylsulfonates - -, therefor.
`
`In column 11, line 30, delete “2-hydroxyproplysulfonic” and
`
`insert - - 2-hydroxypropylsulfonic - -, therefor.
`
`In column 11, line 45, delete “crosslinked” and insert - - cross-linked - -, therefor.
`
`In column 12, line 9, delete “polyvinyl,” and insert - - polyvinyl - -, therefor.
`
`In column 13, line 1, delete “Disoxide,” and insert - - Dioxide, - -, therefor.
`
`In column 13, line 34, delete “materiel” and insert - - material - -, therefor.
`
`In column 14, line 32, delete “Premulen ®” and insert - - Pemulen® - -, therefor.
`
`In column 15, line 24, in Claim 1, delete “005%” and insert - - 0.05%- -, therefor.
`
`In column 15, line 61, in Claim 11, delete “claim 2,” and insert - - claim 6, - -,
`
`0006
`
`0006
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`femn
`
`
`
`Filing Fees for Utility under 35 USC 111(a)
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD(S)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`0007
`
`0007
`
`

`

`Extension-of-Time:
`
`Total in USD ($)
`
`Miscellaneous:
`
`0008
`
`0008
`
`

`

`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`Electronic AcknowledgementReceipt
`
`Application Number:
`
`14222478
`
`International Application Number:
`
`Confirmation Number:
`
`9616
`
`
`
`eC
`
`Paymentinformation:
`
`Charge any Additional Fees required under 37 CFR 1.17 (Patent application and reexamination processing fees)
`
`Deposit Account
`
`Authorized User
`
`010885
`
`WINE, LAURAL.
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpaymentas follows:
`
`Charge any Additional Fees required under 37 CFR 1.16 (National application filing, search, and examination fees)
`
`0009
`
`0009
`
`

`

`Charge any Additional Fees required under 37 CFR 1.19 (Document supplyfees)
`
`Charge any Additional Fees required under 37 CFR 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 CFR 1.21 (Miscellaneous fees and charges)
`
`File Listing:
`
`Pages
`Multi
`File Size(Bytes)/
`DocumentDescription
`Document
`
`
`
`Number Message Digest|Part/.zip|P (if appl.)
`164544
`
`Requestfor Certificate of Correction
`
`COCAllergan1 7618CON6CON1
`AP9248191 pdf
`
`896d 1a453cf219586794f8fadeSfefd8b525q
`808
`
`the application.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`Information:
`
`Information:
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`77d8f5cf7d4c6377"431 bSacaSd39b369a69
`oofs
`
`This AcknowledgementReceipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903indicating acceptanceof the application as a
`national stage submission under35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`0010
`
`0010
`
`

`

`
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Vatent and TrademarkOffice
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`www.uspto.g:
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO.
`
`14/222,478
`
`ISSUE DATE
`
`02/02/2016
`
`51957
`
`7590
`
`01/13/2016
`
`ALLERGAN,INC.
`2525 DUPONT DRIVE,T2-7H
`IRVINE, CA 92612-1599
`
`PATENT NO.
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`9248191
`
`17618CON6CON1 (AP)
`
`9616
`
`The projected patent numberandissue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustmenton the front page.
`
`If a Continued Prosecution Application (CPA) wasfiled in the above-identified application, the filing date that
`determines Patent Term Adjustmentis the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEBsite (http://pair-uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM)at (571)-272-4200.
`
`APPLICANT(s)(Please see PAIR WEBsite http://pair.uspto.gov for additional applicants):
`
`Allergan, Inc., Irvine, CA;
`Andrew Acheampong,Irvine, CA;
`Diane D. Tang-Liu, Las Vegas, CA;
`James N. Chang, Newport Beach, CA;
`David F. Power, San Clemente, CA;
`
`The United States represents the largest, most dynamic marketplace in the world andis an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`worksto encourage andfacilitate business investment. To learn more about why the USAis the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA. gov.
`
`IR103 (Rev. 10/09)
`
`0011
`
`0011
`
`

`

`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`51957
`
`7590
`
`12/18/2015
`
`ALLERGAN, INC.
`2525 DUPONT DRIVE,T2-7H
`IRVINE, CA 92612-1599
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`DATE MAILED: 12/18/2015
`
`17618CON6CONI1 (AP)
`Andrew Acheampong
`03/21/2014
`14/222,478
`TITLE OF INVENTION: METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`9616
`
`
`
`
`
`
`
`
`
`
`
`APPLN. TYPE PUBLICATION FEE DUE|PREV. PAID ISSUE FEEENTITY STATUS ISSUE FEE DUE TOTAL FEE(S) DUE DATE DUE
`
`
`
`
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`03/18/2016
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCEIS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLYTO THIS NOTICE:
`
`I. Review the ENTITY STATUSshownabove.If the ENTITY STATUSis shown as SMALL or MICRO,verify whether entitlement to that
`entity status still applies.
`If the ENTITY STATUSis the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`If the ENTITY STATUSis changed from that shown above, on PART B - FEE(S) TRANSMITTAL,complete section number5 titled
`"Change in Entity Status (from status indicated above)".
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amountof small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL,orits equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE(if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B isfiled, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalentof Part B.
`
`IH. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advisedto the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenancefees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 02/11)
`
`Page | of 3
`
`0012
`
`0012
`
`

`

`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE(if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS"for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS(Note: Use Block 1 for any changeof address)
`
`can only be used for domestic mailings of the
`Note: A certificate of mailing
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`apers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`12/18/2015
`7590
`51957
`States Postal Service with sufficient
`postage for first class mail in an envelope
`ALLERGAN, INC.
`
`: ddressedtothe Mail "EEE address. ab being. facsimil
`
`
`
`
`
`
`addressed
`to
`the Mail Stop ISSUE FEE address above, or
`being
`facsimile
`2525 DUPONT DRIVE, T2-7H
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`IRVINE, CA 92612-1599
`(Depositor's name)
`(Signature)
`
`(ate)
`
`APPLICATION NO.
`
`FILING DATE
`
`
`
`
`
` FIRST NAMED INVENTOR
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`17618CON6CON1 (AP)
`Andrew Acheampong
`03/21/2014
`14/222,478
`TITLE OF INVENTION: METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`9616
`
`
`
`
`
`
`
`APPLN. TYPE PUBLICATION FEE DUE|PREV. PAID ISSUE FEEENTITY STATUS ISSUE FEE DUE TOTAL FEE(S) DUE DATE DUE
`
`
`
`
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`03/18/2016
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`514-020500
`
`2. For printing on the patent front page,list
`(1) The namesofup to 3 registered patent attorneys
`or agents OR,alternatively,
`(2) The nameofa single firm (having as a member a
`2
`registered attorney or agent) and the namesof up to
`2 registered patent attorneys or agents. If nonameis
`listed, no namewill be printed.
`
`
`
`43
`
`
`
`
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`LI Change of correspondence address (or Change of Correspondence
`Address form PTO/SB/122) attached.
`LI "Fee Address" indication (or "Fee Address” Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Numberis required.
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT(printor type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAMEOF ASSIGNEE
`(B) RESIDENCE:(CITY and STATE OR COUNTRY)
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`LV individual LJ Corporation or other private group entity (J Government
`
`4a. The following fee(s) are submitted:
`L] Issue Fee
`_] Publication Fee (No small entity discount permitted)
`LT Advance Order - # of Copies
`
`
`
`4b. Paymentof Fee(s): (Please first reapply any previously paid issue fee shown above)
`LIA checkis enclosed.
`Lj Paymentby credit card. Form PTO-2038 is attached.
`[I The directoris hereby authorized to charge the required fee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number
`(enclose an extra copy ofthis form).
`
`
`
`5. Change in Entity Status (from status indicated above)
`| Applicantcertifying micro entity status. See 37 CFR 1.29
`
` Lj Applicant changing to regular undiscounted fee status.
`
`Lj Applicant asserting small entity status. See 37 CFR 1.27
`
`
`NOTE:Absenta valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue
`fee paymentin the micro entity amountwill not be accepted at the risk of application abandonment.
`
`NOTE:If the application was previously under micro entity status, checking this box will be taken
`to be a notification ofloss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification ofloss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: This form mustbe signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 14 for signature requirements and certifications.
`
`Authorized Signature
`
`Typed or printed name
`
`
`Date
`
`Registration No.
`
`PTOL-85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB0651-0033
`
`USS. Patent and Trademark Office; U.S. DEPARTMENT OF COOMBSCE
`
`Page 2 of 3
`
`0013
`
`

`

`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`APPLICATION NO.
`
`FILING DATE
`
`
`
`
`FIRST NAMED INVENTOR
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`14/222,478
`
`03/21/2014
`
`Andrew Acheampong
`
`17618CON6CONI1 (AP)
`
`9616
`
`51957
`
`7590
`
`12/18/2015
`
`ALLERGAN, INC.
`2525 DUPONT DRIVE, T2-7H
`IRVINE, CA 92612-1559
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`DATE MAILED: 12/18/2015
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(Applicationsfiled on or after May 29, 2000)
`
`The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.
`
`to eliminate the
`Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i)
`requirement that the Office provide a patent term adjustment determination with the notice of allowance. See
`Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer
`providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to
`provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant
`approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the
`patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term
`adjustment) should follow the process outlined in 37 CFR 1.705.
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of
`Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be
`directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.
`
`PTOL-85 (Rev. 02/11)
`
`Page 3 of 3
`
`0014
`
`0014
`
`

`

`OMB Clearance and PRA Burden Statement for PTOL-85 Part B
`
`The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and
`Budget approval before requesting most types of information from the public. When OMB approves an agency
`request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration
`date for the agency to display on the instrument that will be used to collect the information and (ii) requires the
`agency to inform the public about the OMB Control Number’s legal significance in accordance with 5 CFR
`1320.5(b).
`
`The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain
`or retain a benefit by the public whichis to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary
`depending upon the individual case. Any comments on the amount of time you require to complete this form
`and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT
`SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box
`1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to
`respondto a collection of information unlessit displays a valid OMB control number.
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant
`to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this informationis
`35 U.S.C. 2(b)(2); (2) furnishing of the informationsolicited is voluntary; and (3) the principal purpose for which
`the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission
`related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and
`Trademark Office may not be able to process and/or examine your submission, which mayresult in termination of
`proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by youin this form will be subject to the following routine uses:
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records
`may be disclosed to the Department of Justice to determine whether disclosure of these records is required
`by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance
`from the Memberwith respect to the subject matter of the record.
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to
`comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's
`responsibility to recommend improvements in records managementpractices and programs, under authority
`of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations
`governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive.
`Such disclosure shall not be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication
`of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the
`record was filed in an application which became abandoned or in which the proceedings were terminated
`and which application is referenced by either a published application, an application open to public
`inspection or an issued patent.
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency,if the USPTO becomesawareof a violation or potential violation of law or regulation.
`
`0015
`
`0015
`
`

`

`
`
`Applicant-Initiated Interview Summary
`
`
` 14/222,478 ACHEAMPONG ETAL.
`Examiner
`Art Unit
`
`Application No.
`
`Applicant(s)
`
`MARCELAM. CORDERO
`GARCIA
`
`1676
`
`All participants (applicant, applicant’s representative, PTO personnel):
`
`(1) MARCELA M. CORDERO GARCIA.
`
`(2) LAURA L.WINE.
`
`Date of Interview: 77 December 2015.
`
`(3)
`
`(4)
`
`,
`
`,
`
`Type:
`
`[(] Video Conference
`[&X] Telephonic
`[-] Personal[copy given to: [J applicant
`
`[J] applicant’s representative]
`
`Exhibit shown or demonstration conducted:
`If Yes, brief description:
`
`[] Yes
`
`X] No.
`
`[101 [112 [102 (103 [kjOthers
`Issues Discussed
`(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)
`
`Claim(s) discussed: All, in general.
`
`Identification of prior art discussed: US 9,101,574.
`
`Substance of Interview
`(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include:identification or clarification of a
`reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied referencesetc...)
`
`See Continuation Sheet.
`
`
`
`Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP
`section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or
`thirty days from this interview date, or the mailing date of this interview summaryform, whichever islater, to file a statement of the substance of the
`interview
`
`Examinerrecordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of
`the substance of an interview should includethe items listed in MPEP 713.04 for complete and proper recordation including the identification of the
`general thrust of each argumentor issue discussed, a general indication of any other pertinent matters dis

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket